Well that poster sure left it open for further indications, so...

First 21948 Last

Share
Profile

Follow
ChocolateTeapot

378 Posts.

442

19/03/24

08:03

Post #: 72952144
Share

Originally posted by Watmighthavben: ↑

Thanks for your response. I guess I was being greedy in chasing a third, but a second along the gastrointestinal line, within those hard to treat tumours with a huge unmet need. It may not be colorectal, given PD1 Vaxx's venture into that indication in the UK.

I was being presumptuous in thinking it may well be a third as a consequence of the 7 patients with gastrointestinal cancers who received CF33-hNIS alone during dose escalation, and in doing so achieved a disease control rate of 86%, as presented earlier this year at the American Society of Clinical Oncology - Gastrointestinal Cancer Symposium (ASCO-GI).

Who knows? Its interesting though, is it not? As you have correctly noted Imugene have headed down the track of head and neck squamous cell carcinoma, an indication pembroluzimab has exhibited efficacy in. Are any of the patient(s) exhibiting signs of efficacy in the current Vaxinia Trial those dosed in combination with pembroluzimab, or are they in the mono therapy arm? Either way things appear to be progressing nicely.

DYOR

Expand

Well that poster sure left it open for further indications, so let's hope your instinct is right. That's a good observation linking proven pembroluzimab efficacy to the second expansion cancer, I think it bodes well medically and commercially.

I noted the deliberate choice of language on that poster as it says "Other indications" not "An additional". A bold bit of marketing or a real expectation of how this trial will evolve? Definitely very interesting.

IMU Price at posting: 11.0¢ Sentiment: Buy Disclosure: Held
34 Upvote

1 Great analysis

Reply